Pure Global

Alpha-lipoic Acid in Diabetic Nephropathy - Trial NCT06253429

Access comprehensive clinical trial information for NCT06253429 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ain Shams University and is currently Recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06253429
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06253429
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Alpha-lipoic Acid in Diabetic Nephropathy
Oxidative Stress in Children and Adolescents With Diabetic Nephropathy and the Role of Adjuvant Alpha-lipoic Acid as an Antioxidant

Study Focus

Type 1 Diabetes

Thioctic Acid 333 MG Oral Capsule

Interventional

drug

Sponsor & Location

Ain Shams University

Cairo, Egypt

Timeline & Enrollment

Phase 3

Jan 01, 2023

Feb 01, 2024

30 participants

Primary Outcome

Changes in Total antioxidant capacity and Malondialdehyde,Changes in urinary albumin excretion rate

Summary

Endothelial dysfunction in diabetes is a central event in the pathogenesis of different
 microangioapthic changes. Nephropathy in patients with type 1 diabetes is a severe
 microvascular complication.

ICD-10 Classifications

Type 1 diabetes mellitus
Type 1 diabetes mellitus without complications
Type 1 diabetes mellitus with unspecified complications
Type 1 diabetes mellitus with other specified complications
Type 1 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT06253429

Non-Device Trial